MedRhythms secured $25 million in Series B funding to advance its digital therapy platform aimed at measuring and improving someone’s ability to walk after they have experienced a neurologic injury or disease … Company co-founder and CEO Brian Harris was a neurologic music fellow at Spaulding Rehabilitation Hospital in Boston, treating people with stroke and brain deficits with music. He began getting questions from patients and families on how they could access similar care outside of the hospital. Not seeing a suitable alternative, he started MedRhythms with entrepreneur Owen McCarthy in 2016. [Read more…] about Integrating music, movement and stroke rehabilitation, MedRhythms raises $25M to develop and commercialize digital therapeutic
prescription digital therapeutics
Pear Therapeutics to Go Public in Roughly $1.6 Billion SPAC Deal (The Wall Street Journal):
Medical technology company Pear Therapeutics Inc. has agreed to go public by merging with a blank-check company with ties to the Pritzker Vlock Family Office, betting on the growing role of prescription digital therapeutics.
The proposed merger would give the combined company a pro forma equity value of about $1.6 billion. [Read more…] about Prescription software firm Pear Therapeutics to go public via $1.6 billion SPAC deal, harnessing 3 FDA-authorized products and 14 candidates
Akili raises $110m to build its digital therapeutics pipeline (pharmaforum):
EndeavorRx became the first and so far only approved prescription video game treatment in the US when it was cleared by the FDA last year to treat attention-deficit hyperactivity disorder (ADHD), and has also been given a green light in Europe. [Read more…] about Akili Interactive Labs raises $160M in equity and debt to transform cognitive healthcare via prescription videogame treatments
The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017.
Pear said that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treatment of substance use disorder and opioid use disorders, respectively. [Read more…] about Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments